Orbital metastasis from prostate cancer: An atypical case of neuroendocrine dedifferentiation during progression from hormone-sensitive to refractory stage

Clinical Prostate Cancer

Volumn 4, Issue 2, 2005, Pages 134-137

  Challagundla, Suneetha ^a   Gokden, Murat ^b   Viswamitra, Sanjaya ^a   Kohli, Manish ^a,c,d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

Lymphangiogenesis proteins; Prostatic neoplasms; Ptosis; Vascular endothelial growth factor receptor

Indexed keywords

DEXAMETHASONE; DOCETAXEL; ETOPOSIDE; PLATINUM DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; ANDROGEN DEPRIVATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CASE REPORT; DIAGNOSTIC IMAGING; GENE EXPRESSION; HISTOPATHOLOGY; HORMONE RESISTANCE; HORMONE SENSITIVE PROSTATE CANCER; HORMONE SENSITIVITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEUROENDOCRINE DEDIFFERENTIATION; ORBIT METASTASIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PTOSIS; TUMOR BIOPSY; TUMOR DIFFERENTIATION; TUMOR GROWTH;

EID: 26944501561     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2005.n.023     Document Type: Article

References (9)

1. Goldberg RA, Rootman J, Cline RA. Tumors metastatic to the orbit. Surv Ophthalmol 1990; 35:1-24.
2. Ferry AP, Font RL. Carcinoma metastatic to the eye and orbit. Arch Ophthalmol 1974; 92:276-286.
3. Boldt HC, Nerad JA. Orbital metastases from prostate carcinoma. Arch Ophthalmol 1988; 106:1403.
4. Chevalier S, Defoy I, Lacoste J, et al. Vascular endothelial growth factor expression and signaling in the prostate: more than angiogenesis. Mol Cell Endocrinol 2002; 189:169-179.
5. Harper ME, Glynne-Jones E, Goddard L, et al. Vascular endothelial growth factor (VEGF) expression in prostatic tumors and its relationship to neuroendocrine cells. Br J Cancer 1996; 74:910-916.
6. Ismail AH, Altaweel W, Chevalier S, et al. Expression of vascular endothelial growth factor-A in human lymph node metastases of prostate cancer. Can J Urol 2004; 11:2146-2150.
7. Kollerman J, Helpap B. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor FLK-1 in benign, premalignant, and malignant prostate tissue. Am J Clin Pathol 2001; 116:115-121.
8. Papandreou CN, Dalianni DD, Thall PF, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002 15; 20:3072-3080.
9. Kaushal V, Dennis R, Mukunyadzi P, et al. Stage specific expression of VEGF A and D in prostate cancer. Clin Cancer Res 2005; 11(2 pt 1):584-593.